November 20, 2007
AVEO Pharmaceuticals to Present at Lazard Capital Markets 4th Annual Healthcare Conference
CAMBRIDGE, MA, November 20, 2007 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals, is scheduled to present at the Lazard Capital Markets 4th Annual Healthcare Conference on Tuesday, November 27, 2007 at 9:30 a.m. ET at The New York Palace Hotel in New York City.
About AVEO
AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF), as well as collaborations with Merck, OSI Pharmaceuticals and Schering-Plough. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company’s website at http://aveopharma.com/.
